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1. INTRODUCTION {#mgg3846-sec-0005}
===============

Stroke is a major cause of death and disability worldwide and in China, and survivors are usually at high risk of recurrence and poststroke death (Wang, Hu, Sang, Luo, & Yu, [2017](#mgg3846-bib-0035){ref-type="ref"}). Although traditional risk factors potentially explain most of stroke risk, it is generally accepted that multiple genetic variants contribute to the individual‐level heterogeneity in stroke and clinical phenotypes (Markus, [2011](#mgg3846-bib-0022){ref-type="ref"}). Recent evidence has also shown that among individuals at high genetic risk of coronary diseases, adherence to a healthy lifestyle would markedly reduce the relative risk of cardiovascular events and the prevalent subclinical burden of atherosclerosis (Khera et al., [2016](#mgg3846-bib-0015){ref-type="ref"}). Due to the complex nature of stroke, single‐locus method may not be appropriate to study common complex disorders.

Traditionally, the logistic regression model is most often used to explore the risk effects of multiple genetic variants in complex disease, but it has limited power to reveal the interactions between genes only with weak effects (Culverhouse, Suarez, Lin, & Reich, [2002](#mgg3846-bib-0004){ref-type="ref"}; Hoh & Ott, [2003](#mgg3846-bib-0009){ref-type="ref"}). Here, the generalized multifactor dimensionality reduction (GMDR) method (Lou et al., [2007](#mgg3846-bib-0021){ref-type="ref"}) was used in this study, which can not only explore the complex interaction between genetic and environmental factors by collapsing high‐dimensional interactions of genetic data into a single dimension, but also avoid the biased results associated with disease risk by adjusting for the confounding covariates.

In this study, we included a total of 16 variants in eight susceptibility genes which have been assessed in our previous studies to be associated with stroke risk, including apolipoprotein(a) (*APOA1*, OMIM 107680; Sun et al., [2003](#mgg3846-bib-0031){ref-type="ref"}), methylenetetrahydrofolate reductase (*MTHFR*, OMIM 607093; Li et al., [2003](#mgg3846-bib-0017){ref-type="ref"}), vitamin K epoxide reductase complex subunit 1 (*VKORC1*, OMIM 608547; (Wang et al., [2006](#mgg3846-bib-0033){ref-type="ref"}), arachidonate 5‐lipoxygenase‐activating protein (*ALOX5AP*, OMIM 603700; Zhang, Yang, Shi, Sun, & Hui, [2006](#mgg3846-bib-0039){ref-type="ref"}), *NOTCH3* (OMIM 600276)*,* vascular endothelial growth factor (*VEGFA*, OMIM 192240), and kinase insert domain‐containing receptor (*KDR*, also called *VEGF* receptor‐2, OMIM 191306; Zhang et al., [2009](#mgg3846-bib-0038){ref-type="ref"}), and antisense noncoding RNA in the *INK4* locus (*ANRIL*, OMIM 613149) on chromosome 9p21.3 (*Chr.9p21.3*; Zhang et al., [2012](#mgg3846-bib-0036){ref-type="ref"}). These risk genes play critical roles in inflammation, lipid metabolism, endothelial dysfunction, and abnormal vascular remodeling during the development of atherosclerosis. Therefore, in a large case‐control study including 2000 stroke patients and 2000 age‐, gender‐, and demographic‐matched community controls in China, we investigated the risk model of genetic interactions for stroke and subtypes by the GMDR method and then validated these models by the traditional logistic regression model. We further assessed the relationship between genetic interactions and stroke recurrence among patients who have been prospectively followed up for a median of 4.5 years.

In addition, much evidence has shown that carotid artery intima‐media thickness (IMT) is a useful measure of subclinical atherosclerosis and predicts the incidence of cardiovascular diseases (CVD) and stroke (Chambless et al., [2000](#mgg3846-bib-0003){ref-type="ref"}; Polak, Pencina, O\'Leary, & D\'Agostino, [2011](#mgg3846-bib-0024){ref-type="ref"}). In a meta‐analysis with data from 37,197 subjects, Lorenz et al showed that the difference of 0.1 mm in carotid IMT is associated with increased risk of stroke by 13%--18% (Lorenz, Markus, Bots, Rosvall, & Sitzer, [2007](#mgg3846-bib-0020){ref-type="ref"}). Thus, we examined the genetic association with IMT in 1,123 subjects who were randomly selected from a community‐based population without a history of stroke (Zhang et al., [2009](#mgg3846-bib-0038){ref-type="ref"}), so as to explore the possible underlying mechanisms.

Since stroke is a multifactorial disorder, a comprehensive prevention program has been advocated such as hypertension control and lifestyle modification, including not smoking, avoiding obesity, regular physical activity, and a healthy diet pattern (Lloyd‐Jones et al., [2010](#mgg3846-bib-0019){ref-type="ref"}). However, the extent to which genetic risk can be affected by environmental factors remains undetermined. Therefore, in this study, we also analyzed whether environmental factors (including hypertension, smoking, drinking, overweight/obesity, and physical inactivity) could affect the risk of stroke among people at high genetic risk.

2. MATERIALS AND METHODS {#mgg3846-sec-0006}
========================

2.1. Ethical compliance {#mgg3846-sec-0007}
-----------------------

This study was approved by the institutional ethics committees of Fu Wai Hospital and the collaborating hospitals, and all participants signed the informed consent.

2.2. Study population {#mgg3846-sec-0008}
---------------------

The Multicenter Chinese Stroke Study is a large‐scale case‐control study that has been reported in details in our previous studies, including the definition of diagnosis, criteria of inclusion and exclusion, recruitment of case and control subjects, collection of clinical characteristics, and measurement of plasma biochemical variables (Li et al., [2003](#mgg3846-bib-0017){ref-type="ref"}; Sun et al., [2003](#mgg3846-bib-0031){ref-type="ref"}; Wang et al., [2006](#mgg3846-bib-0033){ref-type="ref"}; Zhang et al., [2009](#mgg3846-bib-0038){ref-type="ref"}; Zhang et al., [2012](#mgg3846-bib-0036){ref-type="ref"}). Initially, a total of 2000 consecutive stroke cases (aged 35--74 years) were recruited from seven clinic centers in China from November 2000 to November 2001, and 2000 age‐, gender‐, and resident area‐matched healthy controls were recruited at the same time and at the same demographic area from the local community‐based inhabitants. All cases with first‐onset stroke were diagnosed by neurologists on the basis of clinical symptoms, and brain imaging examination such as computed tomography (CT) or magnetic resonance imaging (\[MRI\]; Adams et al., [1993](#mgg3846-bib-0001){ref-type="ref"}). Three subtypes were recruited: cerebral thrombosis (atherothrombotic stroke), intracerebral hemorrhage, and lacunar infarction. The baseline characteristics of participants were collected by direct patient interviews using a structured questionnaire, including demographic factors, medical history, and lifestyle behaviors, and family history.

In this study, 595 cases and 737 control subjects were excluded because of no plasma data, insufficient DNA quantity, poor DNA quality, or incomplete genotyping data, and finally, 1,405 cases (607 diagnosed as atherothrombotic stroke, 415 as lacunar infarction, and 383 as hemorrhagic stroke) and 1,263 controls were included for analyzing the effects of gene--gene and gene--environment interactions on risk of stroke. No significant differences in clinical characteristics were observed between those excluded and included (Table [S1](#mgg3846-sup-0001){ref-type="supplementary-material"}).

2.3. Follow‐up and outcome assessment {#mgg3846-sec-0009}
-------------------------------------

Stroke cases recruited in this study were prospectively followed up for a median of 4.5 years (from January 2001 to May 2006) by physician investigators via face‐to‐face interview and/or telephone contact with a standard questionnaire as described in our previous studies (Zhang et al., [2009](#mgg3846-bib-0038){ref-type="ref"}; Zhang et al., [2012](#mgg3846-bib-0036){ref-type="ref"}). The end‐points included recurrent events of stroke, all‐cause mortality, and mortality due to CVD. The recurrent stroke events were independently confirmed by the Clinical Endpoint Committee based on the patient medical records and brain imaging. Information on the cause of death was obtained from death certificates and/or medical records when possible, or from family members or care givers.

2.4. Selection and genotyping for genetic risk variants {#mgg3846-sec-0010}
-------------------------------------------------------

Genomic DNA was extracted from peripheral blood leukocytes of the participants using FlexGen Blood DNA Kit according to a standard procedure (Beijing ComWin Biotech Co., Ltd.). In this study, we examined 16 functional variants in eight susceptible genes which have been investigated to be associated with stroke risk in previous studies, and information on the features of variants and genotyping methods is shown in the Table [S2](#mgg3846-sup-0001){ref-type="supplementary-material"}. Briefly, we included a pentanucleotide TTTTA repeat (PNTR) variant in the *APOA1* (NM_000039.1) gene that correlates inversely with plasma Lipoprotein (a) \[Lp(a)\] level (Jurgens et al., [1995](#mgg3846-bib-0014){ref-type="ref"}; Sun et al., [2003](#mgg3846-bib-0031){ref-type="ref"}). The PNTR variation was determined by the method of polymerase chain reaction (PCR)--nondenaturing polyacrylamide gels and DNA sequencing analysis. Single‐nucleotide polymorphisms (SNPs) were the 677C\>T (rs1801133) in *MTHFR* (NM_005957.4) gene that affects the homocysteine metabolism (Li et al., [2003](#mgg3846-bib-0017){ref-type="ref"}; Zhao et al., [2017](#mgg3846-bib-0040){ref-type="ref"}), the 2255T\>C (rs2359612) in *VKORC1* (NM_024006.5) gene that affects the formation of thrombosis and vascular calcification (Wang et al., [2013](#mgg3846-bib-0032){ref-type="ref"}, [2006](#mgg3846-bib-0033){ref-type="ref"}), SG13S114T\>A (rs10507391) and SG13S89G\>A (rs4769874) in the *ALOX5AP* gene (NM_001629.3) that regulates the biosynthesis of proinflammatory leukotrienes (Helgadottir et al., [2004](#mgg3846-bib-0008){ref-type="ref"}; Zhang et al., [2006](#mgg3846-bib-0039){ref-type="ref"}), the 684G\>A (rs1043994) in the *NOTCH3* (NM_000435.2) gene that affects vascular development (Ross et al., [2013](#mgg3846-bib-0026){ref-type="ref"}), six functional SNPs in *VEGFA* (NM_001025366.2) and its receptor *KDR* (NM_002253.3) gene that affects the transcriptional activity and expression (Eichmann & Simons, [2012](#mgg3846-bib-0005){ref-type="ref"}; Zhang et al., [2009](#mgg3846-bib-0038){ref-type="ref"}). These SNPs were genotyped by the method of PCR and restriction fragment length polymorphism (RFLP) analysis. In addition, four SNPs (rs2383206, rs2383207, rs10757278, and rs10757274) at the *Chr.9p21.3* loci that correlate with the *ANRIL* (NM_078487.2) expression and atherosclerosis development (Johnson et al., [2013](#mgg3846-bib-0013){ref-type="ref"}; Smith et al., [2009](#mgg3846-bib-0029){ref-type="ref"}) were included and genotyped by a ligase detection reaction method (Zhang et al., [2012](#mgg3846-bib-0036){ref-type="ref"}).

2.5. Measurements of carotid IMT {#mgg3846-sec-0011}
--------------------------------

The association between genetic interactions and IMT was tested in 1,123 subjects aged 45--83 years (871 men and 252 women) who were randomly selected from a community‐based population without a history of stroke (Zhang et al., [2009](#mgg3846-bib-0038){ref-type="ref"}). The carotid ultrasonography was performed and images were analyzed according to a standardized protocol by a trained physician. The ultrasonography scanning included the right and left common carotid artery (CCA) and internal carotid artery (ICA) at the following locations: proximal CCA (15--30 mm proximal to the carotid bulb), distal CCA (\<15 mm proximal to the carotid bulb), and proximal ICA (carotid bulb, identified by loss of the parallel wall present in the CCA and the initial 10 mm of the vessel above the flow divider between external and internal carotid arteries) (Kiechl & Willeit, [1999](#mgg3846-bib-0016){ref-type="ref"}; Zhang et al., [2009](#mgg3846-bib-0038){ref-type="ref"}). In the analysis, the mean maximum IMT of the left and right arteries was used. The details of IMT measurement were shown in Supplementary materials.

2.6. Statistical analysis {#mgg3846-sec-0012}
-------------------------

The Hardy--Weinberg equilibrium (HWE) of variants was tested for the genotypes distribution in control subjects to assess possible selection bias and genotyping errors. Clinical features between cases and control subjects were compared by Student\'s *t* test for quantitative variables and Chi‐squared test for categorical variables. In the GMDR model, the genotypes of each studied variant were classified into wild‐type genotype (with 0 risk allele), heterozygous genotype (with 1 risk allele), and high‐risk genotype (with 2 risk alleles). Briefly, the GMDR calculates the maximum likelihood estimates and the cumulative score values for all individuals, and if the average score is equal to or higher than a preassigned threshold of 0, the identified genotype combination would be determined as high‐risk model; on the other hand, if the score is lower than 0, it would be determined as low‐risk model (Figure [S1](#mgg3846-sup-0001){ref-type="supplementary-material"}). The score‐based GMDR method uses the data‐reduction strategy to reduce the dimensionality from multidimensional to one‐dimensional, and then identify the specific combinations of genetic factors that show the strongest association with phenotype from all potential combinations. The test accuracy and cross‐validation consistency reach their maxima when the appropriate multi‐locus models are obtained (Hou et al., [2019](#mgg3846-bib-0011){ref-type="ref"}; Lou et al., [2007](#mgg3846-bib-0021){ref-type="ref"}). The algorithm of GMDR was shown in Supplemental methods.

Next, for genetic interaction models identified using the GMDR method, we further assessed their associations with the risk of stroke and its subtypes using the multivariate logistic regression models, so as to ensure not missing some other potentially interesting and important interactions, and odds ratio (OR) with 95% confidence intervals (CIs) were obtained after adjustment for age, gender, and vascular risk factors mentioned above. Multiple comparisons were corrected by false discovery rate at the 0.05 level which was achieved by the Benjamini--Hochberg procedure (Benjamini & Hochberg, [2000](#mgg3846-bib-0002){ref-type="ref"}).

For the gene--environment analysis, persons at low genetic risk with favorable environmental factors served as the reference group, and ORs (95% CI) for the risk of stroke and its subtypes were calculated by the multivariate logistic regression models. The significances of multiplicative interaction between genetic risk model and hypertension as well as each unhealthy lifestyle factor (including smoking, drinking, overweight/obesity, and physical inactivity) were determined by the likelihood ratio test. Hypertension was defined as systolic BP ≥140 mm Hg and/or diastolic BP ≥90 mm Hg, and/or receiving antihypertensive medications, and/or history of hypertension (Liu, [2011](#mgg3846-bib-0018){ref-type="ref"}). Smoking and drinking were classified as "never," "former," or "current". Physical activity was evaluated from responses to questions and classified as "regular exercise (at least once weekly, more than 30 min)" or "inactive (exercise \< once/week)". BMI was classified as normal‐weight (18.5--24 kg/m^2^), overweight (24--28 kg/m^2^), or obesity (≥28 kg/m^2^; He et al., [2014](#mgg3846-bib-0007){ref-type="ref"}).

The Cox proportional model was used to assess the hazards ratio (HR) for relative risks of recurrent stroke events and poststroke mortality associated with recommended genetic model from GMDR analysis. The association between genetic model and carotid IMT (dependent variable) was analyzed by multiple linear regression models. Differences in carotid IMT across the genotype groups were examined by one‐way analysis of variance. Analyses were conducted with [spss]{.smallcaps} software (version 20.0, SPSS Inc). All reported *P* values are two‐sided, and *p* ≤ .05 was considered statistically significant.

3. RESULTS {#mgg3846-sec-0013}
==========

3.1. Clinical characteristics of participants {#mgg3846-sec-0014}
---------------------------------------------

The present study included 1,405 stroke cases and 1,263 controls, and clinical features are shown in Table [1](#mgg3846-tbl-0001){ref-type="table"}. As expected, stroke patients had a higher prevalence of comorbidities including hypertension, diabetes, coronary heart disease, and family history of stroke. These patients were further prospectively followed up for a median of 4.5 years (range, 0.1--6.0 years) to assess the prognosis of stroke. Among them, 72 (5.1%) were lost due to emigration, but no substantial differences were found in baseline characteristics between the follow‐up and lost‐to‐follow‐up subjects (Table [S3](#mgg3846-sup-0001){ref-type="supplementary-material"}). During the follow‐up, 280 recurrent stroke events, 325 cardiovascular disease events, and 261 deaths from all causes (146 from stroke or CHD and 115 from other causes) were recorded.

###### 

Clinical characteristics of stroke cases and control subjects in the present study

  Characteristics                     Control subjects (*n* = 1,263)   Stroke patients                                                                                                                                                                  
  ----------------------------------- -------------------------------- ------------------------------------------------------------ ------------------------------------------------------ ------------------------------------------------------------ ------------------------------------------------------------
  Age, years                          60.0 ± 8.0                       60.5 ± 9.2                                                   58.3 ± 9.6[\*\*](#mgg3846-note-0005){ref-type="fn"}    61.4 ± 9.1[\*\*](#mgg3846-note-0005){ref-type="fn"}          61.1 ± 8.5[\*](#mgg3846-note-0004){ref-type="fn"}
  Men, *n* (%)                        770 (61.0%)                      902 (64.2%)                                                  250 (65.3%)                                            389 (64.1%)                                                  263 (63.4%)
  BMI (kg/m^2^)                       24.16 ± 3.28                     24.25 ± 3.45                                                 24.01 ± 3.56                                           24.21 ± 3.57                                                 24.53 ± 3.13[\*](#mgg3846-note-0004){ref-type="fn"}
  Systolic BP (mmHg)                  129 ± 17                         147 ± 22[\*\*](#mgg3846-note-0005){ref-type="fn"}            152 ± 23[\*\*](#mgg3846-note-0005){ref-type="fn"}      147 ± 23[\*\*](#mgg3846-note-0005){ref-type="fn"}            143 ± 20[\*\*](#mgg3846-note-0005){ref-type="fn"}
  Diastolic BP (mmHg)                 79 ± 10                          88 ± 13[\*\*](#mgg3846-note-0005){ref-type="fn"}             92 ± 13[\*\*](#mgg3846-note-0005){ref-type="fn"}       86 ± 13[\*\*](#mgg3846-note-0005){ref-type="fn"}             86 ± 11[\*\*](#mgg3846-note-0005){ref-type="fn"}
  Fasting glucose (mmol/L)            5.88 ± 1.72                      6.61 ± 2.62[\*\*](#mgg3846-note-0005){ref-type="fn"}         6.57 ± 2.40[\*\*](#mgg3846-note-0005){ref-type="fn"}   6.77 ± 2.80[\*\*](#mgg3846-note-0005){ref-type="fn"}         6.42 ± 2.55[\*\*](#mgg3846-note-0005){ref-type="fn"}
  Lipids (mmol/L)                                                                                                                                                                                                                                       
  Total cholesterol                   5.00 ± 0.99                      4.74 ± 1.01[\*\*](#mgg3846-note-0005){ref-type="fn"}         4.52 ± 0.99[\*\*](#mgg3846-note-0005){ref-type="fn"}   4.84 ± 1.00[\*\*](#mgg3846-note-0005){ref-type="fn"}         4.80 ± 1.00[\*\*](#mgg3846-note-0005){ref-type="fn"}
  Triglycerides                       1.49 (1.05--2.18)                1.66 (1.19--2.41)[\*\*](#mgg3846-note-0005){ref-type="fn"}   1.50 (1.12--2.02)                                      1.71 (1.21--2.50)[\*\*](#mgg3846-note-0005){ref-type="fn"}   1.75 (1.23--2.52)[\*\*](#mgg3846-note-0005){ref-type="fn"}
  HDL‐cholesterol                     1.06 ± 0.31                      0.90 ± 0.28[\*\*](#mgg3846-note-0005){ref-type="fn"}         0.89 ± 0.33[\*\*](#mgg3846-note-0005){ref-type="fn"}   0.90 ± 0.26[\*\*](#mgg3846-note-0005){ref-type="fn"}         0.92 ± 0.26[\*\*](#mgg3846-note-0005){ref-type="fn"}
  LDL‐cholesterol                     3.10 ± 0.91                      2.96 ± 0.92[\*\*](#mgg3846-note-0005){ref-type="fn"}         2.86 ± 0.90[\*\*](#mgg3846-note-0005){ref-type="fn"}   3.03 ± 0.92                                                  2.94 ± 0.93[\*\*](#mgg3846-note-0005){ref-type="fn"}
  Current smoking, *n* (%)            337 (26.7%)                      381 (27.1%)                                                  104 (27.2%)                                            177 (29.2%)                                                  100 (24.1%)
  Current alcohol intake, *n* (%)     318 (25.2%)                      306 (21.8%)[\*](#mgg3846-note-0004){ref-type="fn"}           100 (26.1%)                                            126 (20.8%)[\*](#mgg3846-note-0004){ref-type="fn"}           80 (19.3%)[\*](#mgg3846-note-0004){ref-type="fn"}
  Exercise, *n* (%)                   872 (69.0%)                      646 (46.0%)[\*\*](#mgg3846-note-0005){ref-type="fn"}         135 (35.2%)[\*\*](#mgg3846-note-0005){ref-type="fn"}   267 (44.0%)[\*\*](#mgg3846-note-0005){ref-type="fn"}         244 (58.8%)[\*\*](#mgg3846-note-0005){ref-type="fn"}
  History of hypertension, *n* (%)    342 (27.1%)                      868 (61.8%)[\*\*](#mgg3846-note-0005){ref-type="fn"}         241 (62.9%)[\*\*](#mgg3846-note-0005){ref-type="fn"}   376 (61.9%)[\*\*](#mgg3846-note-0005){ref-type="fn"}         251 (60.5%)[\*\*](#mgg3846-note-0005){ref-type="fn"}
  History of diabetes, *n* (%)        136 (10.8%)                      334 (23.8%)[\*\*](#mgg3846-note-0005){ref-type="fn"}         85 (22.2%)[\*\*](#mgg3846-note-0005){ref-type="fn"}    158 (26.0%)[\*\*](#mgg3846-note-0005){ref-type="fn"}         91 (21.9%)[\*\*](#mgg3846-note-0005){ref-type="fn"}
  History of CHD, *n* (%)             147 (11.6%)                      206 (14.7%)[\*](#mgg3846-note-0004){ref-type="fn"}           32 (8.4%)                                              121 (19.9%)[\*\*](#mgg3846-note-0005){ref-type="fn"}         53 (12.8%)
  Family history of stroke, *n* (%)   298 (23.6%)                      451 (32.1%)[\*\*](#mgg3846-note-0005){ref-type="fn"}         124 (32.4%)[\*\*](#mgg3846-note-0005){ref-type="fn"}   196 (32.3%)[\*\*](#mgg3846-note-0005){ref-type="fn"}         131 (31.6%)[\*\*](#mgg3846-note-0005){ref-type="fn"}

Values are mean ± *SD*, number (percentage), or median (interquartile range), versus control subjects.

Abbreviations: BMI, Body mass index; BP, blood pressure; CHD, coronary heart disease; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein.

*p* \< 0.05.

*p* \< 0.01.
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3.2. GMDR analysis of the gene--gene interactions associated with stroke risk {#mgg3846-sec-0015}
-----------------------------------------------------------------------------

The genotype frequencies of all 16 studied variants in cases and controls are shown in Table [2](#mgg3846-tbl-0002){ref-type="table"} and they did not deviate from the HWE (*p* \> .05). The high‐order interactions were explored for thrombotic stroke, lacunar infarction, hemorrhagic stroke, and overall stroke by the GMDR method. After adjustment for age, gender, and vascular risk factors, the best gene--gene model for overall stroke risk was found to be the interaction between *VKORC1* rs2359612T\>C and *Chr.9p21.3* rs10757274A\>G, which scored 7/10 for cross‐validation consistency and 10 for sign test (*p* = .001; Table [3](#mgg3846-tbl-0003){ref-type="table"}). In addition, one‐locus model of *VKORC1* rs2359612T\>C was also identified for stroke risk, with scores of 9/10 for cross‐validation consistency and 9 for sign test (*p* = .01; Table [3](#mgg3846-tbl-0003){ref-type="table"}). It was reported in our previous study that the presence of the rs2359612C allele of *VKORC1* conferred almost twice the risk of vascular disease (OR 1.95, 95% CI 1.58--2.41, *p* \< .001 for stroke; OR 1.72, 95% CI 1.24--2.38, *p* \< .01 for coronary heart disease; and OR 1.90, 95% CI 1.04--3.48, *p* \< .05 for aortic dissection; Wang et al., [2006](#mgg3846-bib-0033){ref-type="ref"}).

###### 

The genotypes frequency of all 16 studied variants in stroke cases and control subjects

  Gene and variants         Controls (*n* = 1,263)   Stroke cases                                
  ------------------------- ------------------------ --------------- ------------- ------------- -------------
  *APOA1* PNTR                                                                                   
  LRN                       125 (9.9%)               1709 (12.1%)    48 (12.5%)    73 (12.0%)    49 (11.8%)
  HRN                       1,138 (90.1%)            1,235 (87.9%)   335 (87.5%)   534 (88.0%)   366 (88.2%)
  *MTHFR* rs1801133                                                                              
  CC                        410 (32.5%)              412 (29.3%)     116 (30.3%)   173 (28.5%)   123 (29.6%)
  CT                        585 (46.3%)              664 (47.3%)     182 (47.5%)   287 (47.3%)   195 (47.0%)
  TT                        268 (21.2%)              329 (23.4%)     85 (22.2%)    147 (24.2%)   97 (23.4%)
  *VKORC1* rs2359612                                                                             
  TT                        1,099 (87.0%)            1,129 (80.4%)   314 (82.0%)   496 (81.7%)   319 (76.9%)
  TC                        156 (12.4%)              259 (18.4%)     62 (16.2%)    107 (17.6%)   90 (21.7%)
  CC                        8 (0.6%)                 17 (1.2%)       7 (1.8%)      4 (0.7%)      6 (1.4%)
  *ALOX5AP* rs4769874                                                                            
  GG                        1,162 (92.0%)            1,277 (90.9%)   350 (91.4%)   551 (90.8%)   376 (90.6%)
  GA                        96 (7.6%)                122 (8.7%)      32 (8.4%)     52 (8.6%)     38 (9.2%)
  AA                        5 (0.4%)                 6 (0.4%)        1 (0.3%)      4 (0.7%)      1 (0.2%)
  *ALOX5AP* rs10507391                                                                           
  TT                        635 (50.3%)              703 (50.0%)     205 (53.5%)   283 (46.6%)   215 (51.8%)
  TA                        505 (40.0%)              568 (40.4%)     145 (37.9%)   257 (42.3%)   166 (40.0%)
  AA                        123 (9.7%)               134 (9.5%)      33 (8.6%)     67 (11.0%)    34 (8.2%)
  *NOTCH3* rs1043994                                                                             
  GG                        1,027 (81.3%)            1,169 (83.2%)   317 (82.8%)   502 (82.7%)   350 (84.3%)
  GA                        218 (17.3%)              211 (15.0%)     62 (16.2%)    94 (15.5%)    55 (13.3%)
  AA                        18 (1.4%)                25 (1.8%)       4 (1.0%)      11 (1.8%)     10 (2.4%)
  *VEGFA* rs2010963                                                                              
  GG                        386 (30.6%)              436 (31.0%)     135 (35.2%)   190 (31.3%)   111 (26.7%)
  GC                        619 (49.0%)              684 (48.7%)     179 (46.7%)   288 (47.4%)   217 (52.3%)
  CC                        258 (20.4%)              285 (20.3%)     69 (18.0%)    129 (21.3%)   87 (21.0%)
  *VEGFA* rs1570360                                                                              
  GG                        357 (28.3%)              401 (28.5%)     123 (32.1%)   166 (27.3%)   112 (27.0%)
  GA                        628 (49.7%)              709 (50.5%)     184 (48.0%)   300 (49.4%)   225 (54.2%)
  AA                        278 (22.0%)              295 (21.0%)     76 (19.8%)    141 (23.2%)   78 (18.8%)
  *VEGFA* rs833061                                                                               
  TT                        561 (44.4%)              616 (43.8%)     156 (40.7%)   266 (43.8%)   194 (46.7%)
  TC                        566 (44.8%)              628 (44.7%)     176 (46.0%)   273 (45.0%)   179 (43.1%)
  CC                        136 (10.8%)              161 (11.5%)     51 (13.3%)    68 (11.2%)    42 (10.1%)
  *KDR* rs2071559                                                                                
  TT                        624 (49.4%)              713 (50.7%)     168 (43.9%)   342 (56.3%)   203 (48.9%)
  TC                        505 (40.0%)              567 (40.4%)     175 (45.7%)   219 (36.1%)   173 (41.7%)
  CC                        134 (10.6%)              125 (8.9%)      40 (10.4%)    46 (7.6%)     39 (9.4%)
  *KDR* rs1870377                                                                                
  AA                        473 (37.5%)              519 (36.9%)     115 (30.0%)   249 (41.0%)   155 (37.3%)
  AT                        573 (45.4%)              632 (45.0%)     192 (50.1%)   254 (41.8%)   186 (44.8%)
  TT                        217 (17.2%)              254 (18.1%)     76 (19.8%)    104 (17.1%)   74 (17.8%)
  *Chr.9p21.3* rs2383206                                                                         
  AA                        390 (30.9%)              417 (29.7%)     106 (27.7%)   170 (28.0%)   141 (34.0%)
  AG                        631 (50.0%)              674 (48.0%)     187 (48.8%)   289 (47.6%)   198 (47.7%)
  GG                        242 (19.2%)              314 (22.3%)     90 (23.5%)    148 (24.4%)   76 (18.3%)
  *Chr.9p21.3* rs2383207                                                                         
  AA                        171 (13.5%)              192 (13.7%)     59 (15.4%)    72 (11.9%)    61 (14.7%)
  AG                        591 (46.8%)              629 (44.8%)     155 (40.5%)   280 (46.1%)   194 (46.7%)
  GG                        501 (39.7%)              584 (41.6%)     169 (44.1%)   255 (42.0%)   160 (38.6%)
  *Chr.9p21.3* rs10757278                                                                        
  AA                        303 (24.0%)              312 (22.2%)     75 (19.6%)    132 (21.7%)   105 (25.3%)
  AG                        633 (50.1%)              658 (46.8%)     184 (48.0%)   274 (45.1%)   200 (48.2%)
  GG                        327 (25.9%)              435 (31.0%)     124 (32.4%)   201 (33.1%)   110 (26.5%)
  *Chr.9p21.3* rs10757274                                                                        
  AA                        364 (28.8%)              378 (26.8%)     89 (23.2%)    158 (26.0%)   131 (31.6%)
  AG                        642 (50.8%)              667 (47.5%)     186 (48.6%)   284 (46.8%)   197 (47.5%)
  GG                        257 (20.3%)              360 (25.6%)     108 (28.2%)   165 (27.2%)   87 (21.0%)

Abbreviations: *ALOX5AP*, arachidonate 5‐lipoxygenase‐activating protein; *APOA1*, apolipoprotein (a); *Chr.9p21.3*, Chromosome 9p21.3; HRN, high repeat number (sum of both alleles ≥16); *KDR*, kinase insert domain‐containing receptor; LRN, low repeat number (sum of both alleles \<16); *MTHFR*, methylenetetrahydrofolate reductase; PNTR, a pentanucleotide TTTTA repeat; VEGFA, vascular endothelial growth factor; VKORC1, vitamin K epoxide reductase complex subunit 1.
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###### 

The multi‐loci interactions with stroke risk identified by GMDR analysis

  No. of loci   GMDR model                                              Balanced Accuracy   Sign test (*p*)[\*](#mgg3846-note-0008){ref-type="fn"}   Cross‐validation consistency   
  ------------- ------------------------------------------------------- ------------------- -------------------------------------------------------- ------------------------------ -------
  1             9                                                       0.5364              0.5266                                                   9 (.0107)                      9/10
  2             9, 16                                                   0.5476              0.5328                                                   10 (.0010)                     7/10
  3             3, 5, 16                                                0.5587              0.5021                                                   5 (.6230)                      3/10
  4             2, 8, 10, 16                                            0.5869              0.5112                                                   7 (.1719)                      5/10
  5             2, 3, 4, 10, 15                                         0.6311              0.5054                                                   7 (.1719)                      7/10
  6             2, 3, 4, 5, 8, 15                                       0.6967              0.4793                                                   2 (.9893)                      3/10
  7             2, 3, 4, 6, 8, 10, 15                                   0.7814              0.4940                                                   2 (.9893)                      8/10
  8             2, 3, 4, 5, 6, 8, 10, 15                                0.8598              0.4808                                                   2 (.9893)                      9/10
  9             2, 3, 4, 5, 6, 8, 10, 13, 14                            0.9034              0.4658                                                   1 (.9990)                      5/10
  10            2, 3, 4, 5, 6, 7, 8, 10, 13, 14                         0.9343              0.4639                                                   2 (.9893)                      8/10
  11            2, 3, 4, 5, 6, 7, 8, 10, 12, 13, 14                     0.9547              0.5043                                                   7 (.1719)                      10/10
  12            2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13, 14                  0.9661              0.4751                                                   4 (.8281)                      8/10
  13            1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16               0.9743              0.5423                                                   8 (.0547)                      8/10
  14            1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 15, 16           0.9796              0.5047                                                   6 (.3770)                      7/10
  15            1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 15, 16       0.9817              0.5044                                                   6 (.3770)                      7/10
  16            1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16   0.9830              0.5081                                                   7 (.1719)                      10/10

Numbers 1--16 indicate the following studied variations: 1 = PNTR of *ApoA1*, 2 = *MTHFR* 677C\>T, 3 = *VEGFA* rs2010963, 4 = *VEGFA* rs1570360, 5 = *VEGFA* rs833061, 6 = *KDR* rs2071559, 7 = *KDR* rs2305948, 8 = *KDR* rs1870377, 9 = *VKORC1* rs2359612, 10 = *ALOX5AP* rs10507391, 11 = *ALOX5AP* rs4769874, 12 = *NOTCH3* rs1043994, 13 = *Chr.9p21.3* rs2383206, 14 = *Chr.9p21.3* rs2383207, 15 = *Chr.9p21.3* rs10757278, 16 = *Chr.9p21.3* rs10757274.

*p* value was obtained from the GMDR analysis which adjusted for age, gender, BMI, fasting glucose, triglycerides, total cholesterol, HDL‐cholesterol, LDL‐cholesterol, family history of stroke, systolic and diastolic blood pressure, smoking, and drinking status.
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In the hemorrhagic stroke model of GMDR, the best gene--gene interaction was found between *VEGFA* rs833061T\>C and *KDR* rs2305948C\>T, which scored 6/10 for cross‐validation consistency and 10 for sign test (*p* = .001; Table [S4](#mgg3846-sup-0001){ref-type="supplementary-material"}). The one‐locus model of *KDR* rs2305948 was also identified for hemorrhagic stroke, with score of 10 for cross‐validation consistency and sign test (*p* = .001; Table [S4](#mgg3846-sup-0001){ref-type="supplementary-material"}). It was reported in our previous study that subjects carrying the rs2305948T allele of *KDR* had remarkably higher risks for intracerebral hemorrhage (OR 2.20, 95% CI 1.70--2.84, *p* = 1.5 × 10^−9^) and for stroke recurrence (relative risk 1.40, 95% CI 1.12--1.75, *p* \< .003; Zhang et al., [2009](#mgg3846-bib-0038){ref-type="ref"}). Significant high‐order interactions were not detected for atherothrombotic stroke or lacunar infarction (Tables [S5](#mgg3846-sup-0001){ref-type="supplementary-material"} and [S6](#mgg3846-sup-0001){ref-type="supplementary-material"}) by the GMDR analysis.

Since our main purpose was to assess the genetic interactions for stroke risk, the best two‐locus model was mainly analyzed. The associations of the two identified gene--gene interactions with stroke and its subtypes were further validated by the traditional logistic regression model after adjustment for vascular risk factors and correction for multiple comparisons.

For the joint effect of the two genes *VKORC1* and *Chr.9p21.3*, the score distributions by GMDR analysis showed that the genotype combinations of *VKORC1* rs2359612TC/CC and *Chr.9p21.3* rs10757274AG/GG were high‐risk interactive variables (Figure [S2](#mgg3846-sup-0001){ref-type="supplementary-material"}), and thus, individuals with *VKORC1* rs2359612TC/CC and *Chr.9p21.3* rs10757274 AG/GG were grouped as \"risk carriers\" in the logistic regression models. The results showed that when compared to individuals with wild‐type genotypes of *VKORC1* rs2359612TT and *Chr.9p21.3* rs10757274AA, subjects carrying both *VKORC1* rs2359612C and *Chr.9p21.3* rs10757274G had a higher risk for overall stroke (ORs 1.83, 95% CI 1.32--2.52, *p* \< .001, *q* \< 0.016) and atherothrombotic stroke (ORs 1.78, 95% CI 1.20--2.65, *p* = .004, *q* = 0.02; Table [4](#mgg3846-tbl-0004){ref-type="table"}). However, the two genes *VKORC1* and *Chr.9p21.3* had no significant joint effects on the risk of hemorrhagic stroke and lacunar stroke after correction for multiple comparisons (Table [S7](#mgg3846-sup-0001){ref-type="supplementary-material"}).

###### 

The joint effects of *VKORC1* and *Chr.9p21.3* on stroke risk validated by the logistic regression model

  *VKORC1*   *Chr.9p21.3*   Risk of overall stroke    *q‐*value[\#](#mgg3846-note-0011){ref-type="fn"}   Risk of atherothrombotic stroke                                                                  
  ---------- -------------- ------------------------- -------------------------------------------------- --------------------------------- --------- ------------------------- ------------------- ------ ------
  TT         AA             314 (24.9%)/312 (22.2%)   1.00                                                                                           314 (24.9%)/136 (22.4%)   1.00                        
  TT         AG             555 (43.9%)/529 (37.7%)   0.86 (0.68--1.08)                                  .20                               0.32      555 (43.9%)/228 (37.6%)   0.89 (0.66--1.19)   .41    0.47
  TT         GG             230 (18.2%)/288 (20.5%)   1.18 (0.90--1.56)                                  .23                               0.33      230 (18.2%)/132 (21.7%)   1.33 (0.95--1.86)   .10    0.23
  TC         AA             49 (3.9%)/65 (4.6%)       1.56 (0.98--2.48)                                  .06                               0.16      49 (3.9%)/22 (3.6%)       1.22 (0.67--2.23)   .52    0.52
  TC+CC      AG+GG          114 (9.0%)/210 (14.9%)    1.83 (1.32--2.52)                                  \<.001                            \<0.016   114 (9.0%)/89 (14.7%)     1.78 (1.20--2.65)   .004   0.02

Abbreviations: *Chr.9p21.3*, chromosome 9p21.3; CI, confidential interval; ORs, odds ratio; *VKORC1*, vitamin K epoxide reductase complex subunit 1.

ORs (95% CI) and *p* values were obtained by the logistic regression analysis after adjustment for conventional risk factors as in Table [3](#mgg3846-tbl-0003){ref-type="table"}.

*q‐*value (false discovery rate) was obtained with the use of Benjamini--Hochberg procedure for controlling the false positive rate in multiple comparisons.
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For the interactions of *VEGFA* and *KDR,* the genotype combinations of *VEGFA* rs833061 TC/CC and *KDR* rs2305948CT/TT were considered to be high‐risk interactive variables in the score distributions by GMDR analysis (Figure [S3](#mgg3846-sup-0001){ref-type="supplementary-material"}). Thus, individuals with *VEGFA* rs833061TC/CC and *KDR* rs2305948CT/TT were grouped as \"risk carriers\" in further logistic regression analysis. When compared to individuals with wild‐type genotypes of *VEGFA* rs833061TT and *KDR* rs2305948CC, subjects carrying the risk alleles of both *VEGFA* rs833061C and *KDR* rs2305948T had a higher risk for hemorrhagic stroke (ORs 2.30, 95% CI 1.50--3.55, *p* \< .001, *q* \< 0.02; Table [S8](#mgg3846-sup-0001){ref-type="supplementary-material"}). However, the two genes, *VEGFA* and *KDR*, were not found to have significant joint effects on the risk of overall stroke, atherothrombotic stroke, or lacunar infarction (Table [S9](#mgg3846-sup-0001){ref-type="supplementary-material"}). These validations were consistent with the results from GMDR analysis which use the data‐reduction strategy to reduce the dimensionality from multidimensional to one‐dimensional.

3.3. Association of the significant gene--gene interaction model with carotid IMT {#mgg3846-sec-0016}
---------------------------------------------------------------------------------

In the association analysis with carotid IMT, the combination of risk alleles of *VKORC1* rs2359612C and *Chr.9p21.3* rs10757274G was positively associated with the increased IMT (*γ* = .31, *p* = 2.0 × 10^−4^) after adjustment for age, gender, and vascular risk factors with multiple linear regression analysis. The IMT was markedly higher in the subjects carrying both *VKORC1* rs2359612C and *Chr.9p21.3* rs10757274G risk alleles when compared with those having the wild‐type genotypes of *VKORC1* rs2359612TT and *Chr.9p21.3* rs10757274AA (Figure [S4](#mgg3846-sup-0001){ref-type="supplementary-material"}). On the other hand, no association was found between the IMT and variants combination of *VEGFA* rs833061C and *KDR* rs2305948T which increased the risk of hemorrhagic stroke, supporting that stroke subtypes have significantly different pathogenesis and different genetic risk factor profiles.

3.4. Combined effects of environmental/lifestyle and genetic factors on stroke risk {#mgg3846-sec-0017}
-----------------------------------------------------------------------------------

Since stroke is a multifactorial disorder, the extent to which genetic risk can be affected by environmental factors remains undetermined. In this study, we further assessed whether environmental factors (including hypertension, smoking, drinking, physical inactivity, and overweight/obesity) could affect the occurrence of stroke among people at high genetic risks. After adjustment for conventional vascular risk factors and correction for multiple comparisons, we found that hypertension conferred significantly higher risk for stroke regardless of the genetic risk profiles; moreover, hypertensive subjects who carried the combined at‐risk alleles of *VKORC1* rs2359612C and *Chr.9p21.3* rs10757274G would have a remarkably increased risk for stroke (ORs 10.61, 95% CI 6.85--16.44, *q* \< 0.002; *p* \< .001; *P* ~interaction~ = 0.01), compared with those having wild‐type genotypes and without hypertension (Figure [1](#mgg3846-fig-0001){ref-type="fig"}a). For those who lack regular exercise (less than once weekly), the combined at‐risk alleles of *VKORC1* rs2359612C and *Chr.9p21.3* rs10757274G added an additional risk to stroke, with ORs of 6.15 (95% CI 3.60--10.50, *q \< *0.002; *p* for trend \< 0.001; *P* ~interaction~ = 0.01; Figure [1](#mgg3846-fig-0001){ref-type="fig"}b). The statistical data are shown in Tables [S10](#mgg3846-sup-0001){ref-type="supplementary-material"} and [S11](#mgg3846-sup-0001){ref-type="supplementary-material"}. We did not find that lifestyle factors such as smoking, drinking, and overweight/obesity had significant interactions with the two genes *VKORC1* and *Chr.9p21.3* (*P* ~interaction~ \> 0.05), and the risk effects of *VKORC1* rs2359612C and *Chr.9p21.3* rs10757274G on stroke were independent of smoking, drinking, and overweight/obesity after adjustment for conventional risk factors and multiple comparisons (Tables [S12](#mgg3846-sup-0001){ref-type="supplementary-material"} and [S13](#mgg3846-sup-0001){ref-type="supplementary-material"}).

![Jointed effects of the vitamin K epoxide reductase complex subunit 1 (*VKORC1)* and *Chr.9p21.3* interactions with environmental factors on stroke risk. Abbreviations: Ref, reference group. The odds ratio (ORs) and *p* values were calculated by the logistic regression analysis after adjustment for age, gender, and conventional vascular risk factors, and correction for multiple comparisons. (a) Joint effects of the *VKORC1* rs2359612 and *Chr.9p21.3* rs10757274 with hypertension on stroke risk, and the reference group was defined as subjects without hypertension and carrying wild‐type genotypes of rs2359612TT and rs10757274AA; (b) Joint effects of the *VKORC1* rs2359612 and *Chr.9p21.3* rs10757274 with physical inactivity on stroke risk, and the reference group was defined as subjects with regular exercise and carrying wild‐type genotypes of rs2359612TT and rs10757274AA](MGG3-7-e846-g001){#mgg3846-fig-0001}

4. ASSOCIATION OF HIGH‐RISK GENOTYPE COMBINATIONS WITH THE PROGNOSIS OF POSTSTROKE {#mgg3846-sec-0018}
==================================================================================

During a median follow‐up period of 4.5 years for stroke patients, we found that the combined at‐risk alleles of *VKORC1* rs2359612C and *Chr.9p21.3* rs10757274G conferred almost twice the risk for cardiovascular and cerebrovascular diseases, including stroke recurrence (adjusted HR 1.84, 95% CI 1.24--2.73; *p* = .003), CVD events (adjusted HR 1.65, 95% CI 1.15--2.38; *p* = .007), and cardiovascular mortality (adjusted HR, 2.16, 95% CI 1.24--3.79; *p* = .007) in the Cox regression models after adjustment for age, gender, and conventional vascular risk factors (Table [5](#mgg3846-tbl-0005){ref-type="table"}). Next, the Kaplan--Meier curves revealed a significantly higher cumulative hazard rate of stroke recurrence, CVD events, and cardiovascular mortality among patients carrying the combined risk alleles of *VKORC1* rs2359612C and *Chr.9p21.3* rs10757274G as compared with those having wild‐type genotypes of *VKORC1* rs2359612TT and *Chr.9p21.3* rs10757274AA (Figure [2](#mgg3846-fig-0002){ref-type="fig"}).

###### 

Relative risk of cardiovascular outcomes by the *VKORC1* and *Chr.9p21.3* interactions during a longitudinal follow‐up of stroke patients

  *VKORC1* rs2359612   *Chr.9p21.3* rs10757274   Person‐years   Outcomes, *n* (%)   Adjusted Hazards ratio (95% CI)[\*](#mgg3846-note-0013){ref-type="fn"}   *p* value[\*](#mgg3846-note-0013){ref-type="fn"}
  -------------------- ------------------------- -------------- ------------------- ------------------------------------------------------------------------ --------------------------------------------------
  Stroke recurrence                                                                                                                                          
  TT                   AA                        1,293.48       49 (16.4%)          1.00                                                                      
  TT                   AG+GG                     3,272.89       169 (21.7%)         1.45 (1.05--2.00)                                                        .02
  CT                   AA                        256.46         12 (19.7%)          1.41 (0.75--2.66)                                                        .29
  CT+CC                AG+GG                     789.97         50 (25.9%)          1.84 (1.24--2.73)                                                        .003
  CVD events                                                                                                                                                 
  TT                   AA                        1,231.65       61 (20.5%)          1.00                                                                      
  TT                   AG+GG                     3,089.48       194 (24.9%)         1.32 (0.99--1.76)                                                        .06
  CT                   AA                        253.16         13 (21.3%)          1.18 (0.65--2.16)                                                        .59
  CT+CC                AG+GG                     751.52         57 (29.5%)          1.65 (1.15--2.38)                                                        .007
  CVD mortality                                                                                                                                              
  TT                   AA                        1,290.37       23 (7.7%)           1.00                                                                      
  TT                   AG+GG                     3,269.28       93 (11.9%)          1.64 (1.04--2.59)                                                        .04
  CT                   AA                        271.70         3 (4.9%)            0.74 (0.22--2.48)                                                        .63
  CT+CC                AG+GG                     814.07         27 (14.0%)          2.16 (1.24--3.79)                                                        .007

Abbreviations: *Chr.9p21.3*, Chromosome 9p21.3; CVD, cardiovascular diseases; *VKORC1*, vitamin K epoxide reductase complex subunit 1.

Adjusted Hazards ratio (95% CI) and *p* values were obtained by the Cox regression analysis after adjustment for age, gender, BMI, fasting glucose, triglycerides, total cholesterol, HDL‐cholesterol, LDL‐cholesterol, family history of stroke, systolic and diastolic blood pressure, smoking, and drinking status.
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![Kaplan--Meier curves of stroke prognosis among patients who had high‐risk allele combinations of *VKORC1* rs2359612C and *Chr.9p21.3* rs10757274G. CVD, cardiovascular diseases. The red line represented the cumulative hazards of patients who had the combined risk alleles of *VKORC1* rs2359612C and *Chr.9p21.3* rs10757274G, and the blue line as the cumulative hazards of patients who had the wild‐type genotypes of rs2359612TT and rs10757274AA. Log‐rank *p* values were obtained from the Kaplan--Meier analysis after adjustment for conventional risk factors as same as the Cox regression analysis in the Table [5](#mgg3846-tbl-0005){ref-type="table"}. (a) stroke recurrence events; (b) CVD events; (c) Cardiovascular death; (d) All‐cause death](MGG3-7-e846-g002){#mgg3846-fig-0002}

5. DISCUSSION {#mgg3846-sec-0019}
=============

In the present study, we evaluated the multi‐locus interaction on stroke risk by analyzing a total of 16 variants in eight susceptibility genes including *APOA1*, *MTHFR, VKORC1, ALOX5AP, NOTCH3, VEGFA,* and its receptor *KDR*, and *Chr.9p21.3* locus. These risk genes play critical roles in inflammation, lipid metabolism, endothelial dysfunction, and abnormal vascular remodeling during the development of atherosclerosis. We identified for the first time that the genetic interaction of *VKORC1* rs2359612T\>C and *Chr.9p21.3* rs10757274A\>G not only contributed to a higher susceptibility to overall stroke and atherothrombotic stroke, but also a worsen prognosis of poststroke such as stroke recurrence and CVD‐related mortality, after adjustment for age, gender, and conventional risk factors. In addition, the gene--gene interaction of *VEGFA* rs833061C\>T and *KDR* rs2305948T\>C, which are related to abnormal vascular remodeling, was identified to confer a higher risk for hemorrhagic stroke, indicating the different pathogenic mechanisms from atherothrombotic stroke. Furthermore, the gene--environmental interaction analysis showed that hypertension or lack of exercise (less than once weekly) can remarkably increase this risk effect among individuals at high genetic basis combining both *VKORC1* rs2359612C and *Chr.9p21.3* rs10757274G. Lifestyle factors such as smoking, drinking, and overweight/obesity status were not found to have significant interactions with *VKORC1* and *Chr.9p21.3*.

Atherosclerosis is the major pathophysiological mechanism of stroke. The two‐factor genetic interaction between *VKORC1* and *Chr.9p21.3* on stroke risk can be potentially explained by their common biological roles in the inflammatory process and formation of thrombosis. *VKORC1* is a key protein in the recycling of vitamin K and plays a vital role in activating the coagulation cascade and maintaining integrity of the vasculature (Suh et al., [2009](#mgg3846-bib-0030){ref-type="ref"}). The genetic variants of *VKORC1* gene have been reported to affect warfarin dose response and blood clotting through effects on the circle of vitamin K (Schwarz et al., [2008](#mgg3846-bib-0027){ref-type="ref"}), and persons with the risk genotype of rs2359612TT had higher levels of serum undercarboxylated vitamin K‐dependent proteins, which support the association of *VKORC1* gene with coronary heart disease and stroke (Wang et al., [2013](#mgg3846-bib-0032){ref-type="ref"}). *ANRIL*, a newly annotated gene encoding a long antisense noncoding RNA on the *Chr.9p21.3* risk region, regulates the atherosclerotic process such as in thrombogenesis, vascular remodeling and/or repair, and plaque stability (Holdt et al., [2010](#mgg3846-bib-0010){ref-type="ref"}; Jarinova et al., [2009](#mgg3846-bib-0012){ref-type="ref"}). Supporting, our data also provide consistent evidence that the combination of risk alleles in *VKORC1* and *Chr.9p21.3* loci was not only prospectively associated with worse prognosis of poststroke but also correlated with increased IMT, a useful marker of preclinical atherosclerosis.

On the other hand, the two genes *VKORC1* and *Chr.9p21.3* were not identified to have joint effects on the risk of hemorrhagic stroke and lacunar stroke after adjustment for conventional risk factors and multiple comparisons. The pathogenesis of atherothrombotic stroke is mainly involved in the formation and rupture of atherosclerotic plaque in large cerebral vessels, such as anterior, middle and posterior cerebral artery, internal and external carotid artery, vertebral and basilar artery, etc. Obviously, hemorrhagic stroke and lacunar infarction are different from atherothrombotic stroke. Intracerebral hemorrhage often results from long‐term arterial stiffness and arteriolosclerosis, microaneurysms, lipohyalinosis, and cerebral amyloid angiopathy occurring in older people (Qureshi et al., [2001](#mgg3846-bib-0025){ref-type="ref"}). As for lacunar infarction, lacunas result from the occlusion of those small deep penetrating cerebral arteries (with a diameter of \<15 mm).

In our findings, increased risk of hemorrhagic stroke was found to be related with genetic interaction of *VEGFA* rs833061 and *KDR* rs2305948, which may be attributed to the critical role of *VEGFA* and its receptor *KDR* signaling pathway in the development and maintenance of brain vasculature (Greenberg & Jin, [2005](#mgg3846-bib-0006){ref-type="ref"}; Moulton, [2006](#mgg3846-bib-0023){ref-type="ref"}). The lack of sufficient *VEGFA* signaling can result in vascular degeneration and the weak, thin‐walled vessel formation (Shalaby et al., [1995](#mgg3846-bib-0028){ref-type="ref"}), which may reduce vessel compliance and increase the risk of spontaneous vessel wall rupture and hemorrhagic stroke under stress (Qureshi et al., [2001](#mgg3846-bib-0025){ref-type="ref"}). Exonic variant rs2305948, located at the *KDR* binding domain, has been shown to affect the efficiency of *VEGFA* binding to *KDR* (Wang et al., [2007](#mgg3846-bib-0034){ref-type="ref"}); rs833061, located at the promoter region of *VEGFA* gene, can promote the gene transcription and expression level (Zhang et al., [2009](#mgg3846-bib-0038){ref-type="ref"}). Our findings showed that the interaction of these genetic variants further amplified the risk of hemorrhagic stroke, which may be helpful for clarifying the etiology of stroke.

Interestingly, our data showed that hypertension or lack of regular exercise can significantly increase the risk effect among individuals at high genetic basis with both *VKORC1* and *Chr.9p21.3* risk genes. Stroke is a multifactorial disease affected by both genetic and environmental factors, therefore, the extent to which genetic risk can be affected by environmental factors needs to be clarified. Unhealthy lifestyle accompanying with industrialization and urbanization has become increasingly prevalent in China, which may increase the risk of chronic disease including stroke. Our findings regarding the gene--environmental interaction analysis provide additional evidence that blood pressure control and regular exercise are likely to be important strategies for stroke prevention.

The strengths of the study are two aspects. First, the large number of stroke patients allowed us to examine the genetic interactions in different subtypes. In previous studies, the number of hemorrhagic strokes was too small to allow for conclusions as to whether genetic interactions have any effects on this particular subtype of stroke. The second strength included its prospective design, high follow‐up rate, and long‐term follow‐up period. It is the first study to assess whether genetic interactions are associated with the outcome after stroke.

However, some limitations in this study should be mentioned. First, we did not assess all candidate risk genes that have been identified in the Caucasian population by recent genome‐wide association studies. Considering the potential population stratification and difference in ethnicity, we examined the effects of multiple genetic markers based on our previous data in this stroke population, in which no unequal genetic admixture or population stratification was found to affect an association between a genetic variant and disease risk (Wang et al., [2006](#mgg3846-bib-0033){ref-type="ref"}). Second, this study did not repeatedly assess the genetic interactions in an independent stroke cohort, thus more validations are needed in other stroke population. Third, among hemorrhagic stroke patients carrying risk alleles of *VEGFA* and *KDR*, no gene--environmental interactions were observed due to the insufficient sample size, and further studies are needed in larger hemorrhagic stroke cohorts.

In summary, our findings provided novel evidence that people with multiple genetic risk factors can be targets for stroke prevention. The interaction of *VKORC1* and *Chr.9p21.3* was identified to be associated with increased risk of first stroke and its worse prognosis during a longitudinal follow‐up of stroke complications in a Chinese case‐control study. The interaction of *VEGFA* and *KDR* was found to be associated with hemorrhagic stroke. Stroke is highly prevalent in China; therefore, the population‐attributable fraction may be high even if genetic variants confer a modestly relative risk.
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